ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 561,13
1,09%
Dow Jones
39 169,52
0,13%
DAX
18 290,66
0,31%
Brent Oil
86,71
0,21%
Bitcoin
62 976,19
0,20%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) Actualités

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:EPRX
DateHeureSourceTitreSymboleSociété
06/06/202423h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
06/06/202423h00PR Newswire (US)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/06/202413h00PR Newswire (US)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
23/05/202423h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
22/05/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
21/05/202423h00PR Newswire (US)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/05/202413h00PR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/05/202423h03PR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/05/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/04/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/04/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/04/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayNASDAQ:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EPRX

Dernières Valeurs Consultées

EU
LR
Legrand
COIN
ETHUSD
Ethereum
EU
AF
Air FranceKLM
EU
AI
Air Liquide
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
EU
VIV
Vivendi
EU
PX4
SBF 120
EU
ORA
Orange
COIN
BTCUSD
Bitcoin
FTSE
UKX
FTSE 100
NYSE
MCD
McDonalds
EU
BNP
BNP Paribas
EU
RI
Pernod Ricard
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés